Corixa, Idec, GlaxoSmithKline cancer news
CRXA and partner GSK said they filed suit on Sept. 12 against IDPH in the U.S. District Court for the District of Delaware alleging that IDPH's Zevalin radioimmunotherapy infringes three CRXA patents. CRXA's suit follows two suits filed on Sept. 11 by IDPH in the U.S. District Court for the Southern District of California. IDPH's first suit, against CRXA, CRXA's Coulter Pharmaceutical Inc. subsidiary and the University of Michigan, seeks a declaration that Zevalin does not infringe CRXA's radioimmunotherapy patents. The second, filed against GSK, seeks a declaration that IDPH's manufacture of Zevalin does not infringe GSK's patents related to cell culture media.
Both Zevalin and Bexxar radioimmunotherapy, developed by Coulter, are under FDA review to treat non-Hodgkin's lymphoma (NHL). Both products are antibodies targeting CD20, but they use different radiolabels. ...